Drug Profile
Research programme: peripheral vascular disorder therapeutics - BioLineRX
Alternative Names: BL-2050Latest Information Update: 18 Feb 2008
Price :
$50
*
At a glance
- Originator Tel Aviv University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peripheral vascular disorders
Most Recent Events
- 18 Feb 2008 No development reported - Preclinical for Peripheral vascular disorders in Israel (unspecified route)
- 07 Feb 2006 Preclinical trials in Peripheral vascular disorders in Israel (unspecified route)